UY34131A - DOSAGE AND ADMINISTRATION OF ANTI-ERBB3 ANTIBODIES IN COMBINATION WITH THYROSINE KINASE INHIBITORS. - Google Patents

DOSAGE AND ADMINISTRATION OF ANTI-ERBB3 ANTIBODIES IN COMBINATION WITH THYROSINE KINASE INHIBITORS.

Info

Publication number
UY34131A
UY34131A UY0001034131A UY34131A UY34131A UY 34131 A UY34131 A UY 34131A UY 0001034131 A UY0001034131 A UY 0001034131A UY 34131 A UY34131 A UY 34131A UY 34131 A UY34131 A UY 34131A
Authority
UY
Uruguay
Prior art keywords
dosage
administration
combination
kinase inhibitors
erbb3 antibodies
Prior art date
Application number
UY0001034131A
Other languages
Spanish (es)
Inventor
Kubasek William
Moyo Victor
Onsum Matthew David
Nering Rachel
Dhindsa Navreet
Macbeath Gavin
Pearlberg Joseph
Tabah-Fisch Isabelle
Original Assignee
Merrimack Pharmaceuticals Inc
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc, Sanofi Sa filed Critical Merrimack Pharmaceuticals Inc
Publication of UY34131A publication Critical patent/UY34131A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Abstract

Se proporcionan métodos y composiciones para el tratamiento clínico de NSCLC usando anticuerpos anti-ErbB3 combinados con el uso de TKI tales como erlotinib o gefitinib.Methods and compositions are provided for the clinical treatment of NSCLC using anti-ErbB3 antibodies combined with the use of TKI such as erlotinib or gefitinib.

UY0001034131A 2011-06-16 2012-06-15 DOSAGE AND ADMINISTRATION OF ANTI-ERBB3 ANTIBODIES IN COMBINATION WITH THYROSINE KINASE INHIBITORS. UY34131A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161497834P 2011-06-16 2011-06-16
US201161555141P 2011-11-03 2011-11-03
US201261596097P 2012-02-07 2012-02-07
US201261602365P 2012-02-23 2012-02-23
US201261616912P 2012-03-28 2012-03-28

Publications (1)

Publication Number Publication Date
UY34131A true UY34131A (en) 2013-01-31

Family

ID=47357420

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034131A UY34131A (en) 2011-06-16 2012-06-15 DOSAGE AND ADMINISTRATION OF ANTI-ERBB3 ANTIBODIES IN COMBINATION WITH THYROSINE KINASE INHIBITORS.

Country Status (4)

Country Link
AU (1) AU2012271041A1 (en)
TW (1) TW201302792A (en)
UY (1) UY34131A (en)
WO (1) WO2012173867A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1942907A2 (en) * 2005-11-04 2008-07-16 Merck and Co., Inc. Methods of using saha and erlotinib for treating cancer
EP2129396B1 (en) * 2007-02-16 2013-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof

Also Published As

Publication number Publication date
WO2012173867A1 (en) 2012-12-20
AU2012271041A1 (en) 2013-04-04
TW201302792A (en) 2013-01-16

Similar Documents

Publication Publication Date Title
GT201400196A (en) HETEROCICLYL COMPOUNDS
DOP2015000100A (en) INHIBITORS OF THE TIROSINA-QUINASA DE BRUTON
DOP2015000108A (en) PIRROLOPIRIMIDINE COMPOUNDS AS QUINASE INHIBITORS
EA201490194A1 (en) COMBINED THERAPY, INCLUDING CDK4 / 6 INHIBITOR AND PI3K INHIBITOR FOR USE IN CANCER TREATMENT
CO6930363A2 (en) Benzylindazoles substituted for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
CL2015001731A1 (en) Autotaxin inhibitor compounds; pharmaceutical composition and combination; and use in the treatment of diseases such as fibrosis, pruritus, cancer, among others.
CL2015001818A1 (en) Azaindole-derived compounds, protein kinase inhibitors; Preparation method; pharmaceutical composition; and use in the treatment of diseases such as liver cancer, pancreatic cancer, lung cancer, breast cancer, leukemia, among others.
CL2014001103A1 (en) Compounds derived from heteroaryl pyridone and substituted aza-pyridone, btk kinase inhibitors; pharmaceutical composition that includes them; process of preparation of the pharmaceutical composition; pharmaceutical kit; and use for the treatment of immune disorders, cancer, inflammation, neurological disorders, among others.
GT201200321A (en) DERIVATIVES OF HETEROARIL IMIDAZOLONA AS JAK INHIBITORS
EA201490891A1 (en) PYRIDOPYRAZINS, possessing anti-cancer activity through inhibition of FGFR kinase
TR201902525T4 (en) Combination of pyrrolo [2,3-d] pyrimidine derivatives with one or more additional agents as inhibitors of Janus-related kinases (jack).
CL2013000016A1 (en) Compounds derived from imidazopyridine; preparation procedure; Pharmaceutical composition and its use in the treatment of cancer.
UA111075C2 (en) Triazolopyridine compounds as pim kinase inhibitors
CL2014001829A1 (en) Compounds derived from indolizine; preparation procedure; pharmaceutical compositions containing them and use in the treatment of cancer.
PE20191655A1 (en) PHARMACEUTICAL COMBINATIONS
CL2013003227A1 (en) "Substituted indazole-derived compounds, modulators of protein kinase activity; process of obtaining them; in vitro method to inhibit protein kinases; pharmaceutical composition and combination comprising them; and its use in the treatment of cancer "pct
AR089993A1 (en) PEPTIDOMIMETIC MACROCICLES
DOP2013000192A (en) COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK
CL2013000018A1 (en) Compounds derived from indolizine, their preparation procedure; pharmaceutical composition; and use in the treatment of cancer, among others.
PH12015501955A1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
EA201691032A1 (en) IZHOCHROMEN DERIVATIVES AS PHOSFOINOSYTID-3-KINAZ INHIBITORS
CR20140031A (en) DERIVATIVES OF PIRIDIN-2 (1H) -ONA AS JAK INHIBITORS
BR112012027197A2 (en) combination or pharmaceutical composition, its use, kit, and compounds for treating oncological and fibrotic diseases
EA201692313A1 (en) Derivatives of indolysine as inhibitors of phosphosinositide-3-kinase
CL2014000849A1 (en) Compounds derived from substituted benzylindazoles, bub1 kinase inhibitors; manufacturing procedure; pharmaceutical composition; pharmaceutical combination; and its use in the treatment of hyperproliferative diseases.